Scarica l'app Stockscreener
1.9677
15.75%
0.2677
Precedente Chiudi:
$1.70
Aprire:
$1.71
Volume 24 ore:
1,001
Relative Volume:
0.13
Capitalizzazione di mercato:
$9.69M
Reddito:
$2.35M
Utile/perdita netta:
$-2.56M
Rapporto P/E:
-4.4761
EPS:
-0.4396
Flusso di cassa netto:
-
1 W Prestazione:
-2.10%
1M Prestazione:
-0.12%
6M Prestazione:
-8.94%
1 anno Prestazione:
+3.56%
Intervallo 1D:
$1.71
$1.71
Intervallo di 1 settimana:
$1.70
$2.01
Portata 52W:
$1.59
$5.96
Immuron Limited Adr Stock (IMRN) Company Profile
Nome
Immuron Limited Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta IMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.71 | 9.69M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.59 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
719.84 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.77 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.28 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.93 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immuron Limited Adr Borsa (IMRN) Ultime notizie
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event - GlobeNewswire Inc.
Immuron to Present at Q4 Virtual Investor Summit: Gut Disease Pipeline Showcase | IMRN Stock News - StockTitan
Immuron Travelan® continued strong sales growth - Quantisnow
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - The Manila Times
IMRNImmuron Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive Investors Australia
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - Markets Insider
Immuron Plans Phase 2 Trial for IMM-529 following FDA review | Daily Guardian - Daily Guardian Canada
Immuron secures new US DoD research award - Investing.com
Immuron secures new US DoD research award By Investing.com - Investing.com Australia
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Treasuries slip, dollar firm as markets grapple with US politics By Reuters - Investing.com
Curtiss Wright CEO Lynn M Bamford buys $10.2k in stock By Investing.com - Investing.com India
Immuron CEO to present at Sharewise investor event By Investing.com - Investing.com
Immuron to raise up to $2M as part of an ATM equity offering (NASDAQ:IMRN) - Seeking Alpha
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC By ... - Investing.com
Immuron requests pre-IND meeting for IMM-529 with FDA filing - Markets Insider
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529 - Proactive Investors Australia
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com India
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
Immuron Limited Announces Participation in the LD Micro Invitational XIII - The Kingston Whig-Standard
Immuron US DoD Naval Medical Research Center responds to - GlobeNewswire
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak - GlobeNewswire
Immuron Limited Trade Ideas — NASDAQ:IMRN - TradingView
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.33% - Investing.com
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
Pharma & Biotech - Proactive Investors USA
Immuron Limited Adr Azioni (IMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.29%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):